# Study to Assess the Safety, Tolerability, Pharmacokinetic of Thrv-1268

> **NCT06507839** · PHASE1 · COMPLETED · sponsor: **Thryv Therapeutics, Inc.** · enrollment: 56 (actual)

## Conditions studied

- Atrial Fibrillation

## Interventions

- **DRUG:** THRV-1268
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT06507839
- **Lead sponsor:** Thryv Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-05-15
- **Primary completion:** 2024-11-01
- **Final completion:** 2024-11-01
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2025-05-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06507839

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06507839, "Study to Assess the Safety, Tolerability, Pharmacokinetic of Thrv-1268". Retrieved via AI Analytics 2026-09-25 from https://api.ai-analytics.org/clinical/NCT06507839. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*